CJC-1295 (no DAC) + Ipamorelin is a lyophilized research blend that pairs two peptides acting on the growth hormone axis through different receptors. CJC-1295 without DAC is a modified GRF(1-29) analog that acts at the GHRH receptor; ipamorelin is a selective agonist of the ghrelin receptor, GHS-R1a. Each has its own preclinical literature. This overview explains what each component is, why the two are studied side by side, and where the evidence stops.
At a glance
- Type: Two-peptide lyophilized research blend
- Components: CJC-1295 (no DAC) and ipamorelin
- Amounts: The amount of each component is listed on the batch COA
- Receptors: GHRH receptor (CJC-1295 no DAC) and ghrelin receptor GHS-R1a (ipamorelin)
- Regulatory status: Neither is an FDA-approved drug; both fall under WADA S2
Why laboratories study these two side by side
Pituitary somatotroph cells respond to two separate signaling systems. One runs through the GHRH receptor, cloned and characterized in the early 1990s (Mayo, 1992). The other runs through the growth hormone secretagogue receptor, now known as the ghrelin receptor, identified in 1996 (Howard et al., 1996). Because the two receptors are distinct, GH-axis research has long examined agonists of each, alone and together. A combined vial lets a lab work with one representative of each class from a single lot.
The two components
CJC-1295 (no DAC)
CJC-1295 without DAC uses the tetrasubstituted GRF(1-29) backbone described in the ConjuChem work that produced CJC-1295, without the drug affinity complex that binds albumin (Jetté et al., 2005). Research covers GHRH receptor pharmacology, somatotroph regulation and comparison with albumin-binding analogs. Read the full CJC-1295 (no DAC) research overview.
Ipamorelin
Ipamorelin is a synthetic pentapeptide developed by Novo Nordisk and first characterized in 1998 as a selective growth hormone secretagogue (Raun et al., 1998). Research covers GHS-R1a selectivity, GH-axis readouts in rodents and pharmacokinetic-pharmacodynamic modeling (Gobburu et al., 1999). Read the full ipamorelin research overview.
Is there research on the combination?
Studies of GHRH-receptor and ghrelin-receptor agonists given together exist in the broader GH literature, but we are not aware of a peer-reviewed study of this specific pairing, CJC-1295 without DAC combined with ipamorelin, in one preparation.
What the evidence does not show
- The research on each component comes largely from cell, animal and early pharmacology studies. It does not establish any benefit in humans.
- Findings for one peptide cannot be assumed to hold when it is combined with the other.
- No published work has examined this specific blend as a whole.
Regulatory status
Neither component is approved by the FDA as a drug, and both fall under WADA S2 as growth hormone releasing factors. The CJC-1295 (no DAC) + Ipamorelin blend sold by Rogue Compounds is a research reagent for laboratory use only. It is not for human consumption.
Handling and storage in the lab
Lyophilized CJC-1295 (no DAC) + Ipamorelin should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light.
Sourcing and documentation
Rogue Compounds has CJC-1295 (no DAC) + Ipamorelin made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same batch COA, including the amount of each component, is posted on the product page and in the COA Library once testing for the current batch is complete.
View CJC-1295 (no DAC) + Ipamorelin on Rogue Compounds
References
- Thorner MO. The discovery of growth hormone-releasing hormone: an update. J Neuroendocrinol. 2008;20(6):653-654. PMID 18601685
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. PMID 1333056
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID 15817669
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID 10496658
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID 8688086